Nuon Therapeutics Inc., located in the San Francisco Bay Area, is focused on the development and commercialization of new therapies in inflammation and neurological diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS) and neuropathic pain.
The company's approach is focused on developing therapeutic agents either by repurposing existing drugs - which have established safety records - or by acquiring novel drugs to develop and treat unmet medical needs for new indications. Nuon Therapeutics, Inc. has selected the drug Tranilast, N-(3',4'-dimethoxycinnamonyl) anthranilic acid, as its lead therapeutic agent.
Nuon Therapeutics, Inc., originally named Pacific Therapeutics, was founded in Australia and is a private, venture-backed company. In September 2006, the Company raised a US $5 million Series 'A' round of equity funding from GBS Ventures - www.gbsventures.com.au. In July 2007, the Company moved headquarters to the United States and is now a Delaware Corporation with corporate headquarters in the San Francisco Bay Area and operations in Sydney, Australia and London, UK.
Nuon Therapeutics, Inc. has assembled a management team with proven experience in the efficient management of clinical trials. The Scientific Founders, who are involved in the scientific guidance of the company, have demonstrated success in translating scientific advances into practical therapeutics in the chronic inflammatory diseases.